🇺🇸 FDA
Pipeline program

Obinutuzumab

BO21223

Phase 3 small_molecule completed

Quick answer

Obinutuzumab for Non-Hodgkin's Lymphoma is a Phase 3 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Non-Hodgkin's Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials